https://www.selleckchem.com/products/erastin2.html
4%). No NTHL1 p.Q90* homozygotes were identified. Our results indicate that NTHL1 p.Q90* heterozygous carriers do not have an increased risk for breast cancer and that the variant is unlikely to be a significant contributor to breast cancer risk at the population level. Our results indicate that NTHL1 p.Q90* heterozygous carriers do not have an increased risk for breast cancer and that the variant is unlikely to be a significant contributor to breast cancer risk at the population level. To evaluate, in vitro, the fracture load of IPS e
처럼
논평
공유하다
